Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

AbbVie and Eli Lilly have left the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS ... country and they have a demonstrable impact on our ability to operate sustainably in ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...

Eli Lilly posted better-than-expected ... Zepbound posted sales of $2.31bn for the first quarter. Lilly said lower prices for the drug impacted revenue, but demand remained strong.

Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of ...

Risinger also lowered Eli Lilly's price target from $989 to $944 on the formulary news, calling it a negative in a note ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's ...

Although AbbVie, Eli Lilly ... tariff impact. Michaels noted "penalties in the government channel and with existing contracts in the commercial setting" as barriers to hiking drug prices.